Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
AstraZeneca passes prescription medicine rights for Nexium and Vimovo to Grünenthal for $815M
December 3, 2018 Off

AstraZeneca passes prescription medicine rights for Nexium and Vimovo to Grünenthal for $815M

By Dino Mustafić

AstraZeneca will divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal for uprfont payments of $815 million.

FDA accepts Novartis’s Biologics License Application for Zolgesma
December 3, 2018 Off

FDA accepts Novartis’s Biologics License Application for Zolgesma

By Dino Mustafić

Novartis’s Biologics License Application (BLA) for Zolgensma, designed to tackle the genetic root cause of spinal muscular atrophy (SMA) Type 1, a deadly neuromuscular disease, was accepted by the U.S. Food and Drug Administration (FDA).

Mundipharma China to sell Swiss Helsinn’s first cancer supportive care in China
December 3, 2018 Off

Mundipharma China to sell Swiss Helsinn’s first cancer supportive care in China

By Dino Mustafić

Swiss Helsinn Group and Mundipharma China Pharmaceutical will now sell ALOXI IV in China, as it got approval from the…

FDA to review NDA for Shield’s Feraccru
December 3, 2018 Off

FDA to review NDA for Shield’s Feraccru

By Dino Mustafić

Shield Therapeutics said Monday that US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA)…

December 3, 2018 Off

Tiziana Life Sciences completes patient enrollment for Milciclib, topline data by mid 2019

By Dino Mustafić

Tiziana Life Sciences has completed patient enrollment in the ongoing Phase 2a clinical a single-arm, repeated-dose, 6-month duration study of Milciclib for certain patients with unresectable or metastatic HCC, with the topline data from this multi-center trial, being conducted in Italy, Greece and Israel, will be available in the second quarter of 2019.

Shire nets European approval for Takhzyro, which can prevent potentially deadly hereditary angiodema
November 30, 2018 Off

Shire nets European approval for Takhzyro, which can prevent potentially deadly hereditary angiodema

By Dino Mustafić

Shire got the good news from the European Commission (EC) for Marketing Authorisation for Takhzyro injection, for prevention of recurrent…

Redx moves porcupine inhibitor towards the clinic for the treatment of Idiopathic Pulmonary Fibrosis
November 30, 2018 Off

Redx moves porcupine inhibitor towards the clinic for the treatment of Idiopathic Pulmonary Fibrosis

By Dino Mustafić

Redx might have an inhibitor of porcupine enzyme with a potential to treat fibrosis in human patients, it said on…

Oasmia to produce Apealea in Germany with Baxter Oncology
November 29, 2018 Off

Oasmia to produce Apealea in Germany with Baxter Oncology

By Dino Mustafić

Oasmia Pharmaceutical has made a deal with Baxter BioPharma Solutions to manufacture Apealea in its site in Germany, so Oasmia can focus on other products in its own facilities. 

Novartis brings new approved treatment for young people with RRMS (multiple sclerosis) in Europe
November 29, 2018 Off

Novartis brings new approved treatment for young people with RRMS (multiple sclerosis) in Europe

By Dino Mustafić

Novartis’s Gilenya became the first and only oral disease-modifying treatment for young patients with relapsing-remitting forms of multiple sclerosis (RRMS),…

November 28, 2018 Off

Tiziana to test nasal administration of Foralumab for treating inflammatory and autoimmune diseases

By Dino Mustafić

Tiziana Life Sciences has started the first-in-human Phase 1 clinical trial in healthy volunteers for Foralumab , which will be given to…

Posts pagination

Previous 1 … 3,378 3,379 3,380 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine